Rotarix in developing countries: Paving the way for inclusion in national childhood immunization programs in africa

Journal of Infectious Diseases

Volumn 202, Issue SUPPL. 1, 2010, Pages

  Pawinski, Robert ^a   Debrus, Serge ^a   Delem, Andrée ^a   Smolenov, Igor ^a   Suryakiran, Pemmaraju V ^a   Han, Htay Htay ^b  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE;

AFRICA; ASIA; CHILD; CHILD HEALTH CARE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; EUROPE; GASTROENTERITIS; HUMAN; INTUSSUSCEPTION; MALAWI; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; ROTAVIRUS INFECTION; SOUTH AFRICA; SOUTH AND CENTRAL AMERICA; VIRUS ATTENUATION;

ADMINISTRATION, ORAL; AFRICA; ASIA; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; EUROPE; GASTROENTERITIS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; LATIN AMERICA; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 77955706935     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653547     Document Type: Review

References (59)

1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-572.
2. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006; 12:304-306.
3. World Health Organization. Meeting of the Immunization Strategic Advisory Group of Experts April 2009: conclusions and recommendations. Wkly Epidemiol Rec 2009; 84:220-236.
4. Rotavirus Surveillance-Worldwide, 2001-2008.MMWRMorbMortal Wkly Rep 2008; 57:1255-1257.
5. Parashar UD, Burton A, Lanata C, et al.World Health Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200(Suppl 1):S9-S15.
6. Glass RI, Parashar UD, Bresee JS, et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006; 368:323-332.
7. World Health Organization. Conclusions and recommendations from the Immunization Strategic Advisory Group. Wkly Epidemiol Rec 2006; 81:2-11.
8. Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. J Infect Dis 2005; 192(Suppl 1):S160-S166.
9. Grimwood K, Bines JE. Rotavirus vaccines must perform in low-income countries too. Lancet 2007; 370:1739-1740.
10. Ward RL, McNeal MM, Steele AD. Why does the world need another rotavirus vaccine? Ther Clin Risk Manag 2008; 4:49-63.
11. World Health Organization. Report of the meeting on future directions for rotavirus vaccine research in developing countries. Geneva, 9-11 February 2000. http://www.who.int/vaccines-documents/DocsPDF00/ www531.pdf. Accessed January 2009.
12. O'Ryan M. Rotarix (RIX4414): an oral human rotavirus vaccine. Expert Rev Vaccines 2007; 6:11-19.
13. Vesikari T. Rotavirus vaccines. Scand J Infect Dis 2008; 40:691-695.
14. Velázquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996; 335: 1022-1028.
15. Velázquez FR, Matson DO, Guerrero ML, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000; 182:1602-1609.
16. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757-1763.
17. Ruíz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New Engl J Med 2006; 354:11-22.
18. Linhares AC, Velázquez FR, Pérez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: randomised, double-blind controlled study. Lancet 2008; 371: 1181-1189.
19. Phua KB, Lim FS, Lau YL, et al. Human rotavirus vaccine RIX4414 (Rotarix) is highly efficacious in infants from Asia during the first two years of life. In: Program and abstracts of the 13th International Society for Infectious Diseases (Kuala Lumpur, Malaysia). 19-22 June 2008. http://ww2.isid.org/ Downloads/13th-ICID-AbsPosters.pdf. Abstract 19,024. Accessed January 2009.
20. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22:259-267.
21. Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999; 48: 1007.
22. Centers for Disease Control and Prevention. Suspension of rotavirus vaccine after reports of intussusception-United States, 1999. MMWR Morb Mortal Wkly Rep 2004; 53:786-789.
23. Cunliffe NA, Kilgore PE, Bresee JS, et al. Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Bull World Health Organ 1998; 76:525-537.
24. Naghipour M, Nakagomi T, Nakagomi O. Issues with reducing the rotavirus-associated mortality by vaccination in developing countries. Vaccine 2008; 26:3236-3241.
25. World Health Organization. Generic protocols for (i) hospital-based surveillance to estimate the burden of rotavirus gastroenteritis in children and (ii) a community-based survey on utilization of healthcare services for gastroenteritis in children. Geneva: World Health Organization, 2002. http://www.who.int/vaccines-documents/DocsPDF02/ www698.pdf. Accessed January 2009.
26. Nokes DJ, Abwao J, Pamba A, et al. Incidence and clinical characteristics of group A rotavirus infections among children admitted to hospital in Kilifi, Kenya. PLoS Med 2008; 5:e153.
27. Esona MD, Steele D, Kerin T, et al. Determination of the G and P types of previously nontypeable rotavirus strains from the African Rotavirus Network from 1996-2004: identification of unusual G types. J Infect Dis 2010; 202(Suppl 1):S49-S54 (in this supplement).
28. Cunliffe NA. Epidemiology of rotavirus infections in Malawi. J Infect Dis 2009; 202(Suppl 1):S168-S174 (in this supplement).
29. Mwenda JM. African Rotavirus Surveillance Network. J Infect Dis 2009.
30. Steele AD, Ivanoff B. Rotavirus strains circulating in Africa during 1996-1999: emergence of G9 strains and P[6] strains. Vaccine 2003; 21:361-367.
31. Steele AD, Peenze I, de Beer MC, et al. Anticipating rotavirus vaccines: epidemiology and surveillance of rotavirus in South Africa. Vaccine 2003; 21:354-360.
32. Gentsch JR, Laird AR, Bielfelt B, et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 2005; 192(Suppl 1): S146-S159.
33. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15:29-56.
34. Kiulia NM, Kamenwa R, Irimu G, et al. The epidemiology of human rotavirus associated with diarrhoea in Kenyan children: a review. J Trop Pediatr 2008; 54:401-405.
35. Nielsen NM, Eugen-Olsen J, Aaby P, Mølbak K, Rodrigues A, Fischer TK. Characterisation of rotavirus strains among hospitalised and nonhospitalised children in Guinea-Bissau, 2002 A high frequency of mixed infections with serotype G8. J Clin Virol 2005; 34:13-21.
36. Page NA, de Beer MC, Seheri LM, Dewar JB, Steele AD. The detection and molecular characterization of human G12 genotypes in South Africa. J Med Virol 2009; 81:106-113.
37. Vesikari T, Karvonen A, Prymula R, et al. Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries. In: Program and abstracts of the 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (Basel, Switzerland). 3-5 May 2006. http://www.kenes.com/ espid2006/. Accessed January 2009.
38. Tregnaghi M, Lopez P, De Leon T, et al. Oral human rotavirus vaccine RIX4414 (Rotarix) co-administered with routine EPI vaccinations including oral polio vaccine (OPV) is highly efficacious in Latin-America. In: Program and abstracts of the 13th International Society for Infectious Diseases (Kuala Lumpur, Malaysia). 19-22 June 2008. http:// ww2.isid.org/Downloads/13th-ICID- AbsPosters.pdf. Abstract 19,020. Accessed January 2009.
39. Dennehy PH, Bertrand HR, Silas PE, Damaso S, Friedland LR, Abu Elyazeed R. Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States. Pediatrics 2008; 122:e1062-e1066.
40. Zaman K, Sack DA, Yunus M, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009; 27: 1333-1339.
41. Pérez-Schael I, Salinas B, Tomat M, et al. Efficacy of the human rotavirus vaccine Rix4414 in malnourished children. J Infect Dis 2007; 196:537-540.
42. World Health Organization. Health action in crises. Malawi (June 2006). http://www.who.int/hac/crises/mwi/background/Malawi-June06.pdf. Accessed January 2009.
43. de Onis M, Blössner M, Borghi E, Frongillo EA, Morris R. Estimates of global prevalence of childhood underweight in 1990 and 2015. JAMA 2004; 291:2600-2606.
44. Chokephaibulkit K, Kerdpanich A, Vanprapar N, et al. Immunogenicity and vaccine take of RIX4414 (Rotarix) after heat exposure. In: Program and abstracts of the 5th World Congress for the World Society for Paediatric Infectious Diseases (Bangkok, Thailand). 15-18 November 2007. http://www.kenes.com/ wspid2007/program/SessionIndex.asp. Accessed January 2009.
45. United Nations prequalified vaccines. WHO list of vaccines for purchase by UN agencies as of February 2009. http://www.who.int/ immunization-standards/ vaccine-quality/pq-suppliers/en/. Accessed February 2009.
46. Steele AD, De Vos B, Tumbo J, et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2008 (Epub ahead of print).
47. Steele AD, Tumbo J, Reynders J, et al. Comparison of 2 different regimens (two doses versus three doses) in terms of reactogenicity and immunogenicity of the live attenuated human rotavirus vaccine RIX4414 in South African infants. In: Program and abstracts of the 9th International Symposium on Double-Stranded RNA Viruses (Cape Town, South Africa). 21-26 October 2006.
48. Steele AD, Bos P, Tumbo JM, et al. Safety, reactogenicity and immunogenicity of live attenuated human rotavirus vaccine RIX4414 in HIV+ infants in South Africa. In: Program and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/ 46th Annual Meeting of the Infectious Diseases Society of America (Washington DC). 25-28 October 2008.
49. Salinas B, Pérez Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX 4414: A randomized, placebo-controlled trial in LatinAmerican infants. Pediatr Infect Dis J 2005; 24:807-816.
50. Madhi S, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289-298.
51. Anh DD, Thiem VD, Hutagalung Y, et al. Immunogenicity, reactogenicity and safety of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) in Vietnamese infants. In: Program and abstracts of the 13th International Congress on Infectious Diseases (Kuala Lumpur, Malaysia). 19-22 June 2008. http://ww2.isid.org/Downloads/13th-ICID- AbsPosters.pdf. Abstract 19,019. Accessed January 2009.
52. Velasquez AA, Dominguez E, Suryakiran PV, Delem A, Ortega-Barria E, Han HH. Immunogenicity of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) co-administered with childhood vaccinations in Panama. In: Program and abstracts of the 13th International Congress on Infectious Diseases (Kuala Lumpur, Malaysia). 19-22 June 2008. http://ww2.isid.org/ Downloads/13th-ICID-AbsPosters.pdf. Abstract 19,021. Accessed January 2009.
53. Vesikari T, Karvonen A, Suryakiran PV, Smolenov I, Han HH. Immunogenicity and reactogenicity of liquid versus lyophilized formulation of Rotarix (RIX4414) live-attenuated human rotavirus vaccine in Finland. In: Program and abstracts of the 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (Graz, Austria). 13-17 May 2008. http://www.kenes.com/ espid2008/. Accessed January 2009.
54. Global Alliance for Vaccines and Immunisation. Accelerating the introduction of rotavirus vaccines into GAVI-eligible countries. October 2006. http://www.gavialliance.org/resources/19brd-IC-Rota.pdf. Accessed January 2009.
55. Global Alliance for Vaccines and Immunisation. New vaccines co-financing Q&A. http://www.gavialliance.org/resources/Co-financing-QA-en.pdf. Accessed January 2009.
56. Atherley D. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis 2009; 200(Suppl 1):S28-S38.
57. de Oliveira LH, Danovaro-Holliday MC, Matus CR, Andrus JK. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert Rev Vaccines 2008; 7:345-353.
58. Andrus JK, Tambini G, di Fabio JL, Periago MR. Anticipating new vaccines in the Americas. Pan Am J Public Health 2004; 16:369-370.
59. South African Vaccination and Immunisation Centre (SAVIC). South Africa introduced two new vaccines. 30 September 2008. http://www savic.ac.za/news/ newsarticle.php?neseqnp74&pp1&searchp&PHP SESSIDp429d2fc05998f2dc0c636d794212f92c. Accessed January 2009.